Back to results
US 7,803,773 B2Granted
Controlled release formulations of octreotide
AssigneeEndo Pharmaceuticals Solutions Inc.
InventorsPetr Kuzma, Stefanie Decker
Life of this patent
Estimating the term…
Abstract
A formulation of octreotide or pharmaceutically acceptable salts thereof, which provides controlled release of a therapeutically effective amount of octreotide for a period of at least about two months. Methods of treating acromegaly, decreasing growth hormone, decreasing IGF-1, and treating conditions associated with carcinoid tumors and VIPomas by administering a controlled release formulation of octreotide are provided herein.
Claims20
A method of treating a patient suffering from one or more symptoms associated with carcinoid tumors, said method comprising:
- implanting subcutaneously into a patient in need thereof at least one implant comprising a hydrogel and a pharmaceutical formulation comprising octreotide;
- wherein said pharmaceutical formulation is contained within said hydrogel, which hydrogel comprises a copolymer obtained from the copolymerization of a mixture comprising at least two hydrophilic, ethylenically unsaturated monomers;
- wherein said pharmaceutical formulation contains between about 20 to about 150 milligrams of octreotide, in free form or salt form;
- wherein said pharmaceutical formulation further comprises hydroxypropylcellulose;
- and
- wherein said at least one implant releases a therapeutically effective amount of said octreotide to said patient over a period of at least about two months.
3 more elements
Dependencies are inferred from the claim text.